Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-ACVBP vs R-CHOP in DLBCL (60-65 Years)
NCT00135499Phase 3Terminated
- Sponsor
- Lymphoma Study Association
- Start
- Oct 2001
- Primary completion
- Apr 2010
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of vindesine and bleomycin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Lymphoma Study Association. Primary endpoint: Event-Free Survival at 8 years. Started Oct 2001; status: terminated.
02
Drugs
vindesinebleomycin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00135499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135499.